Liquidia Price Target Maintained With a $25.00/Share by Needham
Analysts Have Conflicting Sentiments on These Healthcare Companies: COMPASS Pathways (CMPS), Liquidia Technologies (LQDA) and Regulus (RGLS)
Liquidia Technologies: Legal Wins and Promising Clinical Data Bolster Buy Rating
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $36
Raymond James Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $29
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $35
Liquidia Analyst Ratings
Raymond James Maintains Strong Buy on Liquidia, Raises Price Target to $29
Wells Fargo Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $20
Needham Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
Analysts' Opinions Are Mixed on These Healthcare Stocks: Arcellx Inc (ACLX), Vir Biotechnology (VIR) and Liquidia Technologies (LQDA)
Favorable Court Decision and Market Potential Propel Liquidia Technologies' Buy Rating
Scotiabank Maintains Liquidia(LQDA.US) With Buy Rating, Raises Target Price to $36
Liquidia Is Maintained at Sector Outperform by Scotiabank
Liquidia Price Target Raised to $36.00/Share From $34.00 by Scotiabank
Liquidia Analyst Ratings
Scotiabank Remains a Buy on Liquidia Technologies (LQDA)
Needham Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $25
LifeSci Capital Maintains Liquidia(LQDA.US) With Buy Rating, Maintains Target Price $35
Positive Outlook for Liquidia Technologies: Buy Rating Affirmed Following Legal Victory and Anticipated FDA Approval